2020/December - Latest news from KCE Trials

The whole KCE Trials team wishes you all the best for the festive season and good health and happiness for 2021.  

Please see below the latest news from the KCE Trials funding Programme. 

Open calls for proposals –funding opportunities

Two calls for proposals are currently open: the BeNeFIT-2 call (a collaboration with ZonMw in the Netherlands, this call will close mid-January) and the Covid-19 fast track rolling call for clinical studies

Recruitment has finished for our first COVID-19 funded study! 

COV-AID, a study on blocking interleukin-6 and interleukin-1 pathways in patients with systemic cytokine release syndrome, has successfully finished recruitment of 342 patients in 16 sites. First results are expected early next year. Congratulations to the team at UZ Gent and all collaborating hospitals for this achievement. Check out our dashboard to see who participated in this trial.

To date, KCE Trials has funded four RCTs evaluating potential covid-19 treatments, for a total budget of € 7.5M. Almost 1000 patients of the planned 1,475 have already been recruited by 33 Belgian hospitals.

Progress in funded studies

We are happy to announce the following important milestones have been reached:
preciseFPI (First Patient In) in Belgium for the PRECISE study. Investigating whether giving more protein than usual in patients admitted to intensive care can reduce muscle breakdown and speed up recovery. This study is part of the BeNeFit call and is a collaboration between Maastricht UMC and Ziekenhuis Oost-Limburg (ZOL) in Genk. Prof Dieter Mesotten is the Coordinating Investigator for Belgium.  The study is expected to last 27 months. 

TrialsFast recruitment: with more than 450 patients (of the planned 1,014) recruited in the first 3 months, the GonoScreen study is off to a flying start ! The study will assess if men who have sex with men (MSM) benefit from routine screening every 3 months for gonorrhoea and chlamydia if they do not have any symptoms or if screening should only be done when symptomatic, as it may represent an unnecessary burden and potentially contribute to antibiotic resistance. The Sponsor of the study is the Institute for Tropical Medicine, and the Chief Investigator is Dr Chris Kenyon. The study is expected to last 26 months. 

Check our dynamic dashboard for real-time recruitment data for all KCE Trials funded studies


KCE Trials (NL/FR/EN)
+32 2 287 33 88
Published on: